ERBB2 and neoplasm: Four well-defined clinical subgroups, Luminal A, Luminal B, human epidermal growth factor receptor-2 (HER2) positive and triple negative (TN) show significantly different tumor growth and prognosis as well as therapeutic options (Perou et al. 2000; Szymiczek et al. 2021).